Delta Dental of Michigan has invested $3 million in Interleukin Genetics to advance the company's periodontal disease susceptibility risk test.
The investment includes the purchase of 500,000 shares of Interleukin's convertible preferred stock, according to the company. In return, Interleukin expects to receive net proceeds of approximately $2.7 million after deducting fees and expenses.
Delta Dental also will obtain one board seat as part of the deal. Delta Dental of Michigan has supported the company's efforts to advance its periodontal disease susceptibility risk test.
Interleukin develops and markets a line of genetic tests under the Inherent Health and PST brands.
